2024-05-28 10:04:32
Daewoong Pharmaceutical participates within the US ‘Digestive Illness Organisation’ for 2 consecutive years
‘Pexuclu’ educational sales space offered 4 main analysis outcomes
‘Pexuclu Evening’ symposium held together with educational societies
Over 100 docs from 8 international locations attended… Lectures, case evaluation, and many others.
Daewoong Pharmaceutical introduced on the twenty eighth that it participated within the ‘2024 Digestive Illness Week (DDW)’ held in Washington, DC, USA. We operated a Pexuclu educational sales space and even held a individually ready ‘Pexuclu Evening’ symposium. DDW is taken into account the world’s largest worldwide convention on gastroenterology, attended by medical employees, researchers, and trade officers from all over the world. It’s stated that about 13,000 folks visited this yr’s occasion.
Within the case of Daewoong Pharmaceutical, it participated in DDW for 2 consecutive years following final yr. He arrange a Pexu Clue sales space to share the newest data and reveal 12 key analysis outcomes. Amongst them, a poster was offered together with three researcher-led fundamental research on anti-inflammatory results and one extra evaluation outcome from a section 3 scientific trial in sufferers with erosive gastroesophageal reflux illness in China. Poster presentation matters embody anti-inflammatory properties of fexuprazan by means of inhibition of nuclear issue kappabee (NF-Kb) in Helicobacter pylori-positive gastric epithelial cells, anti-inflammatory results by means of inhibition of pyroptosis pathway in esophageal cells, and non-steroids. These embody the impact of stopping small gut harm in a mouse mannequin induced by NSAIDs, and the wonderful impact of relieving principal signs of Fexuclu in Chinese language sufferers with erosive reflux gastroesophageal reflux illness.
The Pexuclu Evening Symposium was held on the Washington DC Marriott Lodge on the nineteenth. About 100 docs from eight international locations, together with Korea, Brazil, Colombia, and Mexico, attended the symposium. Professor Hoon-Yong Jeong of Asan Medical Middle and Professor Max Schmulson of the Nationwide Autonomous College of Mexico (UNAM) served as moderators. On the symposium, lectures and displays had been held on the efficacy of Fexuclu, which has been confirmed by means of numerous scientific trials, and the effectiveness of the P-CAB sequence remedy, which is superior to the PPI sequence.
Within the first session, Professor Ronnie Fass of Case Western Reserve College, a world-renowned authority within the area of gastroesophageal reflux illness, primarily mentioned the disadvantages of PPI-based therapies, the justification for utilizing P-CAB-based therapies, and the clinically confirmed results of Fexuclu remedy. The lecture was given with content material. At this occasion, Professor Ronnie Pas additionally launched current scientific information proving the effectiveness of Fexuclu in reflux pharyngitis.
Within the second session, Professor Gwangha Kim of Pusan Nationwide College School of Medication and Professor Ann Sandy offered a case research that confirmed the effectiveness of Fexuclu in bettering persistent cough signs and Helicobacter pylori eradication remedy. Professor Gwangha Kim defined the mechanism of reflux pharyngitis and the diagnostic standards and difficulties based mostly on instances and launched the wonderful cough symptom enchancment impact of Fexuclu. On at the present time, Professor Kim introduced, “Fexuclu has confirmed to be simpler than PPI-based therapies in sufferers with extreme signs,” and added, “We anticipate it to turn into a serious remedy within the space of persistent cough enchancment sooner or later.”
Park Eun-kyung, head of ETC Advertising and marketing Division at Daewoong Pharmaceutical, stated, “Collaborating on this DDW and working a sales space and symposium had been significant as a venue for change to advertise the Pexuclu model to digestive illness specialists all over the world and share the newest associated data.” “We’ll work more durable to determine ourselves as an efficient choice for treating gastroesophageal reflux illness within the remedy area,” he stated.
Daewoong Pharmaceutical’s Fexuclu is Korea’s thirty fourth new drug launched in Korea in July 2022. It’s a third-generation P-CAB remedy that shortly and stably suppresses gastric acid secretion by bettering the shortcomings of current gastroesophageal reflux illness therapies, H2RA (histamine-2 receptor antagonist) and PPI remedy. The remedy comfort is great as it may be taken as soon as a day no matter meals, and Fexuclu has a half-life of as much as 9 hours, so it’s stated to be efficient in bettering nighttime heartburn signs. It has additionally been confirmed to be efficient in relieving persistent cough signs attributable to excessively secreted abdomen acid refluxing into the esophagus and aggravating the mucous membrane.
Kim Min-beom, Donga.com reporter [email protected]
-
- nice
- 0canine
-
- I am so unhappy
- 0canine
-
- I am indignant
- 0canine
-
- I like to recommend it
- canine
Scorching information now
2024-05-28 10:04:32